Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study

INTRODUCTION: Treatments like glucagon-like peptide-1 receptor agonists carry low hypoglycemia risk and are recommended for elderly patients with type 2 diabetes (T2D), while some routine treatments, like insulin, increase hypoglycemia risk. The DISPEL-Advance (Dulaglutide vs Basal InSulin in Inject...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoog, Meredith, Paczkowski, Rosirene, Huang, Ahong, Halpern, Rachel, Buysman, Erin, Stackland, Sydnie, Zhang, Yiran, Wangia-Dixon, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570245/
https://www.ncbi.nlm.nih.gov/pubmed/37740872
http://dx.doi.org/10.1007/s13300-023-01473-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570245/
https://www.ncbi.nlm.nih.gov/pubmed/37740872
http://dx.doi.org/10.1007/s13300-023-01473-7

Ejemplares similares